Review: omalizumab reduces asthma exacerbations and daily steroid use


Clinical impact ratings GP/FP/Primary care ⭐⭐⭐⭐⭐ IM/Ambulatory care ⭐⭐⭐⭐⭐
Respirology ⭐⭐⭐⭐⭐

Q In patients with asthma, how effective is omalizumab, a recombinant humanised monoclonal antibody, in reducing asthma exacerbations and steroid use?

METHODS

Data sources: searching Cochrane Airways Group trials register, scanning the reference lists of relevant studies and review articles, reviewing abstracts presented at leading respiratory society meetings, contacting pharmaceutical companies manufacturing anti-immunoglobulin E (IgE) formulations, and contacting experts in the field

Study selection and assessment: randomised controlled trials comparing anti-IgE at any dose or route with placebo or conventional treatments in children and adults with chronic asthma.

Outcomes: reduction or termination of steroid use and asthma exacerbations (hospital admissions, emergency department visits, days lost from work or school, unscheduled physician visits, and increase in medication).

MAIN RESULTS

8 blinded, placebo controlled trials of fair to high quality met the inclusion criteria (n = 2037). Omalizumab was administered by inhaler in 1 trial, intravenously in 3 trials, and subcutaneously in 4 trials. Results were reported for the stable steroid phase and the steroid reduction phase. During these phases, fewer patients who received omalizumab had >1 asthma exacerbation (table). During the steroid reduction phase, more patients who received omalizumab discontinued inhaled steroid use or had >50% reduction in use (table). In both phases, patients who received omalizumab required less rescue medication and had fewer asthma symptoms (p < 0.05). The 1 trial of inhaled omalizumab showed no difference from placebo in the outcomes measured.

CONCLUSION

In patients with asthma, intravenous or subcutaneous omalizumab reduces asthma exacerbations when used as adjunctive or steroid sparing therapy and reduces inhaled steroid use.

Abstract and commentary also appear in ACP Journal Club.

For correspondence: Dr S Walker, National Respiratory Training Centre, Warwick, UK. s.walker@nrtc.org.uk
Source of funding: Garfield Weston Foundation UK.

Omalizumab vs placebo for chronic asthma at up to 24 weeks*

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Number of trials</th>
<th>Steroid phase</th>
<th>Omalizumab</th>
<th>Placebo</th>
<th>RRR (95% CI)</th>
<th>RBI (CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥1 exacerbation</td>
<td>3</td>
<td>Stable steroid</td>
<td>14%</td>
<td>26%</td>
<td>46% (33 to 57)</td>
<td>9 (7 to 13)</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>Steroid reduction</td>
<td>18%</td>
<td>33%</td>
<td>44% (33 to 54)</td>
<td>7 (6 to 10)</td>
</tr>
<tr>
<td>≥50% reduction in steroid use</td>
<td>4</td>
<td>Steroid reduction</td>
<td>40%</td>
<td>21%</td>
<td>85% (58 to 116)</td>
<td>6 (5 to 8)</td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>Steroid reduction</td>
<td>76%</td>
<td>56%</td>
<td>35% (26 to 45)</td>
<td>5 (5 to 7)</td>
</tr>
</tbody>
</table>

*Abbreviations defined in glossary; RRR, RBI, NNT, and CI calculated from data in article using a fixed effects model.

Commentary

The role of monoclonal anti-IgE antibodies in clinical asthma management continues to evolve. Developed to neutralise and sequester circulating IgE antibodies in allergic people, this treatment seems to have more complex immunological effects than initially realised. Other beneficial effects include the down regulation of IgE receptors on mast cells and basophils, and altering allergen presentation to the immune system, thereby preventing sensitisation.

The meta-analysis by Walker et al confirms the clinical benefits of anti-IgE therapy, including the reduction of asthma exacerbations and decreasing the requirement for preventive inhaled steroids. Other studies show improvement in quality of life and lung function, suggesting a clinical benefit that reflects its wide ranging immunological effects.

Furthermore, this benefit is evident in a range of asthma severity including severe asthma where IgE was thought to be less important. Hence, anti-IgE is not simply a steroid sparing treatment but seems to have other effects that cannot be achieved by inhaled steroids alone. Together with the fact that it can be injected every 2–4 weeks, it is a new method of asthma treatment with benefits that are additive and complementary to currently available mediation.

However, the major limitation of anti-IgE currently is its cost to benefit ratio. The cost of the medication is currently about US$10 000 per year, which far exceeds other forms of asthma treatment. From this point of view, the cost to benefit ratio still favours inhaled steroids and long acting β agonists as the foundation of achieving good asthma control in most patients. Nevertheless, there are patients maintained on optimal doses of these medications who continue to have poor asthma control or achieve it only with unacceptable side effects. In such patients, the direct and indirect costs of poor asthma control and frequent asthma exacerbations may well justify the cost of anti-IgE therapy. Looking ahead, if the cost of biotechnology and the price of this medication falls, it will be an adjunct to, and may well supplant, currently available inhaled steroids and long acting β agonists even in patients with mild asthma.

Frank Thien, MD, FRACP, FCCP
Alfred Hospital & Monash University
Melbourne, Victoria, Australia